Biobank for patients with aggressive tumors
Official title: Analysis of the Immunogenetic Profile of Patients With Aggressive Course of Malignant Neoplastic Process Resistant to the Standard Treatment Approaches: a Translational Study
Run by N.N. Petrov National Medical Research Center of Oncology · NCT05539677 · Data updated 2026-11-12
This study is collecting blood and tumor samples from patients with aggressive cancers to see if they can find clues to create better, personalized treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | N.N. Petrov National Medical Research Center of Oncology Academic / other |
| Locations | 1 site (Saint Petersburg) |
| Status | Recruiting |
| Started | September 1998 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | May 6, 2024 |
| Trial ID | NCT05539677 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with histologically verified solid tumors who are currently receiving systemic therapy and can provide biosamples.
✕Probably not a fit
Patients with concurrent lymphoproliferative disorders or those who have undergone stem cell or bone marrow transplantation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect blood and tumor tissue samples from patients with various malignant solid tumors, including brain tumors, melanoma, soft tissue sarcoma, and colorectal cancer. The collected samples will be analyzed to assess immunological factors, including blood cell subpopulations and tumor-specific antigens, alongside clinical data such as treatment responses and patient demographics. The goal is to identify potential biomarkers that could help tailor treatment strategies for individual patients.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with aggressive tumors.
How similar studies have gone: Other studies focusing on biomarker discovery in similar patient populations have shown promise, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed inform consent * Histolgically verified solid tumour * Receiving systemic therapy for neoplasm * Has archival tumour tissue * Provide biosamples with living tumour tissue or blood samples for immunologic assessment Exclusion Criteria: * Concurrent Lymphoprolipherative disorder * Patients after stem cell or bone marrow thansplantation * Incomplete informaton on previous cancer history or medical history * Patients with known primary immunodeficiency * Patients receiving immunosupressive therapy for concurrent illness * Pregnant patients
Where it's running
-
N.N. Petrov NMRC of Oncology, Oncoimmunology dep.
Saint Petersburg, Russia Recruiting
Study contacts
- Study coordinator: Aleksei Novik, MD, PhD
- Email: alexey.viktorovich.novik@gmail.com
- Phone: +78124399505
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues
This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.
-
A network for collaborative cancer research in Ontario
This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.
-
Florida ASCENT Program
This project will test whether combining the MyCarePulse EHR platform with ASCENT patient navigators helps adults with recent cancer diagnoses in Florida improve food security, diet quality, and confidence in healthy eating compared with standard care.
-
IDOV-Immune for advanced solid tumors
This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.
-
Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer
This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.
-
Understanding the experiences of patients with chronic cancer treatments
This study is trying to understand how people with advanced chronic cancer feel about their targeted treatments by having them share their experiences through interviews and creative expressions like art and music.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.